Joseph P. Hagan
2014 - Orexigen Therapeutics
In 2014, Joseph P. Hagan earned a total compensation of $1.7M as Former Chief Business and Financial Officer at Orexigen Therapeutics, a 11% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $178,248 |
|---|---|
| Option Awards | $1,141,672 |
| Salary | $379,250 |
| Other | $7,980 |
| Total | $1,707,150 |
Hagan received $1.1M in option awards, accounting for 67% of the total pay in 2014.
Hagan also received $178.2K in non-equity incentive plan, $379.3K in salary and $8K in other compensation.
Rankings
In 2014, Joseph P. Hagan's compensation ranked 5,201st out of 13,032 executives tracked by ExecPay. In other words, Hagan earned more than 60.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,201 out of 13,032 | 60th |
Division Manufacturing | 1,858 out of 4,966 | 63rd |
Major group Chemicals And Allied Products | 620 out of 1,686 | 63rd |
Industry group Drugs | 472 out of 1,365 | 65th |
Industry Pharmaceutical Preparations | 375 out of 1,043 | 64th |
Source: SEC filing on May 27, 2016.
Hagan's colleagues
We found four more compensation records of executives who worked with Joseph P. Hagan at Orexigen Therapeutics in 2014.
News
Regulus Therapeutics CEO Joseph Hagan's 2021 pay falls 22% to $1.8M
April 27, 2022
Regulus Therapeutics CEO Joseph Hagan's 2020 pay rises 16% to $2.3M
April 30, 2021
Regulus Therapeutics CEO Joseph Hagan's 2019 pay slips 14% to $2M
April 29, 2020
Regulus Therapeutics CEO Joseph Hagan's 2018 pay jumps 22% to $2.3M
July 1, 2019